Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Insights into Imaging
Published in: Insights into Imaging 1/2020

01-12-2020 | Magnetic Resonance Imaging | Critical Review

Imaging diagnosis of metastatic breast cancer

Authors: Filippo Pesapane, Kate Downey, Anna Rotili, Enrico Cassano, Dow-Mu Koh

Published in: Insights into Imaging | Issue 1/2020

Login to get access

Abstract

Numerous imaging modalities may be used for the staging of women with advanced breast cancer. Although bone scintigraphy and multiplanar-CT are the most frequently used tests, others including PET, MRI and hybrid scans are also utilised, with no specific recommendations of which test should be preferentially used. We review the evidence behind the imaging modalities that characterise metastases in breast cancer and to update the evidence on comparative imaging accuracy.
Literature
1.
Tan W, Yang M, Yang H, Zhou F, Shen W (2018) Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers. Cancer Manag Res 10:4333–4347PubMedPubMedCentralCrossRef
2.
3.
4.
Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474CrossRefPubMed
5.
Amin MB, Greene FL, Edge SB et al (2017) The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 67:93–99PubMedCrossRef
6.
American Cancer Society. Breast cancer survival rates by stage. In, 2019
7.
Lee SJ, Park S, Ahn HK et al (2011) Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancer. Cancer Res Treat 43:89–95PubMedPubMedCentralCrossRef
8.
Pinker K, Chin J, Melsaether AN, Morris EA, Moy L (2018) Precision medicine and radiogenomics in breast cancer: new approaches toward diagnosis and treatment. Radiology 287:732–747PubMedCrossRef
9.
Jacobs MA, Macura KJ, Zaheer A et al (2018) Multiparametric whole-body MRI with diffusion-weighted imaging and ADC mapping for the identification of visceral and osseous metastases from solid tumors. Acad Radiol 25:1405–1414PubMedPubMedCentralCrossRef
10.
Godinho MV, Lopes F, Costa FM (2018) Whole-body magnetic resonance imaging for the assessment of metastatic breast cancer. Cancer Manag Res 10:6743–6756PubMedPubMedCentralCrossRef
11.
Tsao MN (2015) Brain metastases: advances over the decades. Ann Palliat Med 4:225–232PubMed
12.
Penco S, Rotili A, Pesapane F et al (2020) MRI-guided vacuum-assisted breast biopsy: experience of a single tertiary referral cancer centre and prospects for the future. Med Oncol 37:36PubMedCrossRef
13.
Pesapane F, Suter MB, Rotili A et al (2020) Will traditional biopsy be substituted by radiomics and liquid biopsy for breast cancer diagnosis and characterisation? Med Oncol 37:29PubMedCrossRef
14.
Houssami N, Ciatto S, Macaskill P et al (2008) Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol 26:3248–3258PubMedCrossRef
15.
Cardoso F, Senkus E, Costa A et al (2018) 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)dagger. Ann Oncol 29:1634–1657PubMedCrossRef
16.
Cardoso F, Kyriakides S, Ohno S et al (2019) Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 30:1674PubMedCrossRef
17.
Costelloe CM, Rohren EM, Madewell JE et al (2009) Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol 10:606–614PubMedCrossRef
18.
Aebi S, Davidson T, Gruber G, Cardoso F, ESMO Guidelines Working Group (2011) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 22 Suppl 6:vi12-vi24
19.
The Royal College of Radiologists. Recommendations for cross-sectional imaging in cancer management, breast cancer. In: Clinical Radiology, 2014:BFCR(14)12
20.
Colzani E, Johansson AL, Liljegren A et al (2014) Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics. Br J Cancer 110:1378–1384PubMedPubMedCentralCrossRef
21.
Chikarmane SA, Tirumani SH, Howard SA, Jagannathan JP, DiPiro PJ (2015) Metastatic patterns of breast cancer subtypes: what radiologists should know in the era of personalized cancer medicine. Clin Radiol 70:1–10PubMedCrossRef
22.
Lee SC, Jain PA, Jethwa SC, Tripathy D, Yamashita MW (2014) Radiologist’s role in breast cancer staging: providing key information for clinicians. Radiographics 34:330–342PubMedCrossRef
23.
NCCN.​org. Breast cancer screening and diagnosis version 3.2018. In: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), 2018
24.
Gradishar WJ, Anderson BO, Balassanian R et al (2018) Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 16:310–320PubMedCrossRef
25.
Lecouvet FE, Talbot JN, Messiou C et al (2014) Monitoring the response of bone metastases to treatment with magnetic resonance imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer 50:2519–2531PubMedCrossRef
26.
Bjurlin MA, Turkbey B, Rosenkrantz AB, Gaur S, Choyke PL, Taneja SS (2018) Imaging the high-risk prostate cancer patient: current and future approaches to staging. Urology 116:3-12
27.
Daldrup-Link HE, Franzius C, Link TM et al (2001) Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 177:229–236PubMedCrossRef
28.
Lecouvet FE, El Mouedden J, Collette L et al (2012) Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99 m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 62:68–75PubMedCrossRef
29.
Shen G, Deng H, Hu S, Jia Z (2014) Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol 43:1503–1513PubMedCrossRef
30.
Love C, Din AS, Tomas MB, Kalapparambath TP, Palestro CJ (2003) Radionuclide bone imaging: an illustrative review. Radiographics 23:341–358PubMedCrossRef
31.
Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT (2004) Bone imaging in metastatic breast cancer. J Clin Oncol 22:2942–2953PubMedCrossRef
32.
Eustace S, Tello R, DeCarvalho V et al (1997) A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. AJR Am J Roentgenol 169:1655–1661PubMedCrossRef
33.
Rybak LD, Rosenthal DI (2001) Radiological imaging for the diagnosis of bone metastases. Q J Nucl Med 45:53–64PubMed
34.
Giovanella L, Castellani M, Suriano S et al (2011) Multi-field-of-view SPECT is superior to whole-body scanning for assessing metastatic bone disease in patients with prostate cancer. Tumori 97:629–633PubMedCrossRef
35.
Nozaki T, Yasuda K, Akashi T, Fuse H (2008) Usefulness of single photon emission computed tomography imaging in the detection of lumbar vertebral metastases from prostate cancer. Int J Urol 15:516–519PubMedCrossRef
36.
Palmedo H, Marx C, Ebert A et al (2014) Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients. Eur J Nucl Med Mol Imaging 41:59–67PubMedCrossRef
37.
Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I (2006) The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 47:287–297PubMed
38.
39.
Han LJ, Au-Yong TK, Tong WC, Chu KS, Szeto LT, Wong CP (1998) Comparison of bone single-photon emission tomography and planar imaging in the detection of vertebral metastases in patients with back pain. Eur J Nucl Med 25:635–638PubMedCrossRef
40.
Venkitaraman R, Sohaib A, Cook G (2007) MRI or bone scan or both for staging of prostate cancer? J Clin Oncol 25:5837–5838 author reply 5838-5839PubMedCrossRef
41.
Schirrmeister H, Glatting G, Hetzel J et al (2001) Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med 42:1800–1804PubMed
42.
Abikhzer G, Gourevich K, Kagna O, Israel O, Frenkel A, Keidar Z (2016) Whole-body bone SPECT in breast cancer patients: the future bone scan protocol? Nucl Med Commun 37:247–253PubMedCrossRef
43.
Jacobson AF, Fogelman I (1998) Bone scanning in clinical oncology: does it have a future? Eur J Nucl Med 25:1219–1223PubMedCrossRef
44.
Rigaud J, Tiguert R, Le Normand L et al (2002) Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol 168:1423–1426PubMedCrossRef
45.
Schirrmeister H, Guhlmann A, Elsner K et al (1999) Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med 40:1623–1629
46.
Helyar V, Mohan HK, Barwick T et al (2010) The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate. Eur J Nucl Med Mol Imaging 37:706–713PubMedCrossRef
47.
Heindel W, Gubitz R, Vieth V, Weckesser M, Schober O, Schafers M (2014) The diagnostic imaging of bone metastases. Dtsch Arztebl Int 111:741–747PubMedPubMedCentral
48.
Hagemeister FB Jr, Buzdar AU, Luna MA, Blumenschein GR (1980) Causes of death in breast cancer: a clinicopathologic study. Cancer 46:162–167PubMedCrossRef
49.
50.
Ghobrial FEI, Eldin MS, Razek A, Atwan NI, Shamaa SSA (2017) Computed tomography assessment of hepatic metastases of breast cancer with revised Response Evaluation Criteria in Solid Tumors (RECIST) criteria (version 1.1): inter-observer agreement. Pol J Radiol 82:593–597PubMedPubMedCentralCrossRef
51.
Floriani I, Torri V, Rulli E et al (2010) Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging 31:19–31PubMedCrossRef
52.
Kennecke H, Yerushalmi R, Woods R et al (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277PubMedCrossRef
53.
Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRef
54.
Brookes M, MacVicar D, Husband J (2007) Metastatic carcinoma of the breast: the appearances of metastatic spread to the abdomen and pelvis as demonstrated by CT. Br J Radiol 80:284–292PubMedCrossRef
55.
Mhlanga JC, Evans AE, Doyle S et al (2011) The prognostic significance of computerised tomography findings in women with liver metastases from breast cancer. Breast 20:455–459PubMedCrossRef
56.
Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363:1938–1948PubMedCrossRef
57.
Kaplan MA, Ertugrul H, Firat U et al (2015) Brain metastases in HER2-positive metastatic breast cancer patients who received chemotherapy with or without trastuzumab. Breast Cancer 22:503–509PubMedCrossRef
58.
Perez-Lopez R, Mateo J, Mossop H et al (2017) Diffusion-weighted imaging as a treatment response biomarker for evaluating bone metastases in prostate cancer: a pilot study. Radiology 283:168–177PubMedCrossRef
59.
Ghanem N, Altehoefer C, Hogerle S et al (2002) Comparative diagnostic value and therapeutic relevance of magnetic resonance imaging and bone marrow scintigraphy in patients with metastatic solid tumors of the axial skeleton. Eur J Radiol 43:256–261PubMedCrossRef
60.
Daffner RH, Lupetin AR, Dash N, Deeb ZL, Sefczek RJ, Schapiro RL (1986) MRI in the detection of malignant infiltration of bone marrow. AJR Am J Roentgenol 146:353–358PubMedCrossRef
61.
Schirrmeister H, Guhlmann A, Kotzerke J et al (1999) Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 17:2381–2389PubMedCrossRef
62.
Steinborn MM, Heuck AF, Tiling R, Bruegel M, Gauger L, Reiser MF (1999) Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr 23:123–129PubMedCrossRef
63.
Horvath LJ, Burtness BA, McCarthy S, Johnson KM (1999) Total-body echo-planar MR imaging in the staging of breast cancer: comparison with conventional methods--early experience. Radiology 211:119–128PubMedCrossRef
64.
Walker R, Kessar P, Blanchard R et al (2000) Turbo STIR magnetic resonance imaging as a whole-body screening tool for metastases in patients with breast carcinoma: preliminary clinical experience. J Magn Reson Imaging 11:343–350PubMedCrossRef
65.
Altehoefer C, Ghanem N, Hogerle S, Moser E, Langer M (2001) Comparative detectability of bone metastases and impact on therapy of magnetic resonance imaging and bone scintigraphy in patients with breast cancer. Eur J Radiol 40:16–23PubMedCrossRef
66.
Kim DS, Hong SH, Choi JY et al (2009) Magnetic resonance imaging diagnoses of bone scan abnormalities in breast cancer patients. Nucl Med Commun 30:736–741PubMedCrossRef
67.
Houssami N, Costelloe CM (2012) Imaging bone metastases in breast cancer: evidence on comparative test accuracy. Ann Oncol 23:834–843PubMedCrossRef
68.
Schmidt GP, Reiser MF, Baur-Melnyk A (2009) Whole-body MRI for the staging and follow-up of patients with metastasis. Eur J Radiol 70:393–400PubMedCrossRef
69.
Michaels AY, Keraliya AR, Tirumani SH, Shinagare AB, Ramaiya NH (2016) Systemic treatment in breast cancer: a primer for radiologists. Insights Imaging 7:131–144PubMedCrossRef
70.
71.
Braga L, Semelka RC, Pietrobon R, Martin D, de Barros N, Guller U (2004) Does hypervascularity of liver metastases as detected on MRI predict disease progression in breast cancer patients? AJR Am J Roentgenol 182:1207–1213PubMedCrossRef
72.
73.
74.
Kruger S, Mottaghy FM, Buck AK et al (2011) Brain metastasis in lung cancer. Comparison of cerebral MRI and 18F-FDG-PET/CT for diagnosis in the initial staging. Nuklearmedizin 50:101–106PubMedCrossRef
75.
Ramakrishna N, Temin S, Lin NU (2018) Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO clinical practice guideline update summary. J Oncol Pract 14:505–507PubMedCrossRef
76.
Thoeny HC, Barbieri S, Froehlich JM, Turkbey B, Choyke PL (2017) Functional and targeted lymph node imaging in prostate cancer: current status and future challenges. Radiology 285:728–743PubMedCrossRef
77.
Petren-Mallmin M, Andreasson I, Ljunggren O et al (1998) Skeletal metastases from breast cancer: uptake of 18F-fluoride measured with positron emission tomography in correlation with CT. Skeletal Radiol 27:72–76PubMedCrossRef
78.
Even-Sapir E, Metser U, Flusser G et al (2004) Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 45:272–278PubMed
79.
Cook GJ, Azad GK, Goh V (2016) Imaging bone metastases in breast cancer: staging and response assessment. J Nucl Med 57(Suppl 1):27S–33SPubMedCrossRef
80.
Dashevsky BZ, Goldman DA, Parsons M et al (2015) Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype. Eur J Nucl Med Mol Imaging 42:1666–1673PubMedPubMedCentralCrossRef
81.
Israel O, Goldberg A, Nachtigal A et al (2006) FDG-PET and CT patterns of bone metastases and their relationship to previously administered anti-cancer therapy. Eur J Nucl Med Mol Imaging 33:1280–1284PubMedCrossRef
82.
Catalano OA, Daye D, Signore A et al (2017) Staging performance of whole-body DWI, PET/CT and PET/MRI in invasive ductal carcinoma of the breast. Int J Oncol 51:281–288PubMedCrossRef
83.
Koolen BB, Vrancken Peeters MJ, Aukema TS et al (2012) 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat 131:117–126PubMedCrossRef
84.
Brennan ME, Houssami N (2012) Evaluation of the evidence on staging imaging for detection of asymptomatic distant metastases in newly diagnosed breast cancer. Breast 21:112–123PubMedCrossRef
85.
Minamimoto R, Loening A, Jamali M et al (2015) Prospective comparison of 99mTc-MDP scintigraphy, combined 18F-NaF and 18F-FDG PET/CT, and whole-body MRI in patients with breast and prostate cancer. J Nucl Med 56:1862–1868PubMedCrossRef
86.
Antoch G, Vogt FM, Freudenberg LS et al (2003) Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 290:3199–3206PubMedCrossRef
87.
Melsaether AN, Raad RA, Pujara AC et al (2016) Comparison of whole-body (18)F FDG PET/MR imaging and whole-body (18)F FDG PET/CT in terms of lesion detection and radiation dose in patients with breast cancer. Radiology 281:193–202PubMedCrossRef
88.
Birim O, Kappetein AP, Stijnen T, Bogers AJ (2005) Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg 79:375–382PubMedCrossRef
89.
Schmidt GP, Baur-Melnyk A, Haug A et al (2008) Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. Eur J Radiol 65:47–58PubMedCrossRef
90.
Bluemel C, Krebs M, Polat B et al (2016) 68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18F-choline-PET/CT. Clin Nucl Med 41:515–521PubMedPubMedCentralCrossRef
91.
92.
Schaarschmidt BM, Grueneisen J, Heusch P et al (2015) Oncological whole-body staging in integrated (18)F-FDG PET/MR: value of different MR sequences for simultaneous PET and MR reading. Eur J Radiol 84:1285–1292PubMedCrossRef
93.
Huellner MW, de Galiza BF, Husmann L et al (2016) TNM staging of non-small cell lung cancer: comparison of PET/MR and PET/CT. J Nucl Med 57:21–26PubMedCrossRef
94.
Grueneisen J, Sawicki LM, Schaarschmidt BM et al (2016) Evaluation of a fast protocol for staging lymphoma patients with integrated PET/MRI. PLoS One 11:e0157880PubMedPubMedCentralCrossRef
95.
Grueneisen J, Schaarschmidt BM, Heubner M et al (2015) Implementation of FAST-PET/MRI for whole-body staging of female patients with recurrent pelvic malignancies: a comparison to PET/CT. Eur J Radiol 84:2097–2102PubMedCrossRef
96.
Catalano OA, Nicolai E, Rosen BR et al (2015) Comparison of CE-FDG-PET/CT with CE-FDG-PET/MR in the evaluation of osseous metastases in breast cancer patients. Br J Cancer 112:1452–1460PubMedPubMedCentralCrossRef
97.
Raad RA, Friedman KP, Heacock L, Ponzo F, Melsaether A, Chandarana H (2016) Outcome of small lung nodules missed on hybrid PET/MRI in patients with primary malignancy. J Magn Reson Imaging 43:504–511PubMedCrossRef
98.
Riola-Parada C, Garcia-Canamaque L, Perez-Duenas V, Garcerant-Tafur M, Carreras-Delgado JL (2016) Simultaneous PET/MRI vs PET/CT in oncology. a systematic review. Rev Esp Med Nucl Imagen Mol 35:306–312PubMed
99.
Matsubayashi RN, Fujii T, Yasumori K, Muranaka T, Momosaki S (2010) Apparent diffusion coefficient in invasive ductal breast carcinoma: correlation with detailed histologic features and the enhancement ratio on dynamic contrast-enhanced MR Images. J Oncol 2010:821048
100.
Padhani AR, Liu G, Koh DM et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102–125PubMedPubMedCentralCrossRef
101.
Rotili A, Trimboli RM, Penco S et al (2020) Double reading of diffusion-weighted magnetic resonance imaging for breast cancer detection. Breast Cancer Res Treat 180(1):111–120
102.
Koh DM, Blackledge M, Padhani AR et al (2012) Whole-body diffusion-weighted MRI: tips, tricks, and pitfalls. AJR Am J Roentgenol 199:252–262PubMedCrossRef
103.
Lauenstein TC, Freudenberg LS, Goehde SC et al (2002) Whole-body MRI using a rolling table platform for the detection of bone metastases. Eur Radiol 12:2091–2099PubMedCrossRef
104.
Ma J, Costelloe CM, Madewell JE et al (2009) Fast dixon-based multisequence and multiplanar MRI for whole-body detection of cancer metastases. J Magn Reson Imaging 29:1154–1162PubMedCrossRef
105.
Heusner TA, Kuemmel S, Koeninger A et al (2010) Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging 37:1077–1086PubMedCrossRef
106.
Gutzeit A, Doert A, Froehlich JM et al (2010) Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. Skeletal Radiol 39:333–343PubMedCrossRef
107.
Schmidt GP, Schoenberg SO, Schmid R et al (2007) Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 17:939–949PubMedCrossRef
108.
Padhani AR, van Ree K, Collins DJ, D'Sa S, Makris A (2013) Assessing the relation between bone marrow signal intensity and apparent diffusion coefficient in diffusion-weighted MRI. AJR Am J Roentgenol 200:163–170PubMedCrossRef
109.
Dietrich O, Geith T, Reiser MF, Baur-Melnyk A (2017) Diffusion imaging of the vertebral bone marrow. NMR Biomed 30
110.
Engelhard K, Hollenbach HP, Wohlfart K, von Imhoff E, Fellner FA (2004) Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer. Eur Radiol 14:99–105PubMedCrossRef
111.
Harmon SAS, Bergvall E, Mena E et al (2018). A prospective comparison of (18)F-sodium fluoride PET/CT and PSMA-targeted (18)F-DCFBC PET/CT in metastatic prostate cancer. J Nucl Med 59:1665–1671
112.
McCann TE, Kosaka N, Turkbey B, Mitsunaga M, Choyke PL, Kobayashi H (2011) Molecular imaging of tumor invasion and metastases: the role of MRI. NMR Biomed 24:561–568PubMed
113.
Czarniecki M, Pesapane F, Wood BJ, Choyke P, Turkbey B (2018) Ultra-small superparamagnetic iron oxide contrast agents for lymph node staging of high-risk prostate cancer. Transl Androl Urol 7(Suppl 4):S453–S461
114.
Harisinghani MG, Dixon WT, Saksena MA et al (2004) MR lymphangiography: imaging strategies to optimize the imaging of lymph nodes with ferumoxtran-10. Radiographics 24:867–878PubMedCrossRef
115.
Birkhauser FD, Studer UE, Froehlich JM et al (2013) Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol 64:953–960PubMedCrossRef
116.
Fortuin AS, Bruggemann R, van der Linden J et al (2018) Ultra-small superparamagnetic iron oxides for metastatic lymph node detection: back on the block. Wiley Interdiscip Rev Nanomed Nanobiotechnol 10:1471
117.
Corot C, Robert P, Idee JM, Port M (2006) Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 58:1471–1504PubMedCrossRef
118.
Harisinghani MG, Barentsz J, Hahn PF et al (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348:2491–2499PubMedCrossRef
119.
Reimer P, Jahnke N, Fiebich M et al (2000) Hepatic lesion detection and characterization: value of nonenhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging, and spiral CT-ROC analysis. Radiology 217:152–158PubMedCrossRef
120.
Kobayashi H, Kawamoto S, Saga T et al (2001) Novel liver macromolecular MR contrast agent with a polypropylenimine diaminobutyl dendrimer core: comparison to the vascular MR contrast agent with the polyamidoamine dendrimer core. Magn Reson Med 46:795–802PubMedCrossRef
121.
Vogl TJ, Kummel S, Hammerstingl R et al (1996) Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 200:59–67PubMedCrossRef
122.
Metser U, Berlin A, Halankar J et al (2018) (18)F-Fluorocholine PET whole-body MRI in the staging of high-risk prostate cancer. AJR Am J Roentgenol 210:635–640PubMedCrossRef
Metadata
Title
Imaging diagnosis of metastatic breast cancer
Authors
Filippo Pesapane
Kate Downey
Anna Rotili
Enrico Cassano
Dow-Mu Koh
Publication date
01-12-2020
Publisher
Springer Berlin Heidelberg
Published in
Insights into Imaging / Issue 1/2020
Electronic ISSN: 1869-4101
DOI
https://doi.org/10.1186/s13244-020-00885-4

Other articles of this Issue 1/2020

Insights into Imaging 1/2020 Go to the issue

Original Article

Artificial intelligence abstracts from the European Congress of Radiology: analysis of topics and compliance with the STARD for abstracts checklist

Educational Review

Imaging of mandibular fractures: a pictorial review

Educational Review

Gallstones top to toe: what the radiologist needs to know

Educational Review

Thoracic abnormal air collections in patients in the intensive care unit: radiograph findings correlated with CT

Educational Review

Pre- and post-operative imaging of cochlear implants: a pictorial review

Educational Review

Convolutional neural networks for brain tumour segmentation